Bristol-Myers signs HIV drug technology transfer agreement with Brazil
PRINCETON, N.J. — Bristol-Myers Squibb Company has entered into a technology transfer agreement with the Brazilian Ministry of Health to expand access to HIV drug Reyataz® (atazanavir sulfate) in that country, according to a press release.
The agreement is designed to build the capacity and skills required for the Brazilian government to produce a sustainable, high quality supply of atazanavir and will enable the government to become, over time, the sole source of atazanavir in Brazil.
Bristol-Myers Squibb has worked collaboratively with the government of Brazil for many years to help improve and sustain access to HIV therapy in the country, in recognition of the government’s demonstrated commitment to universal access.“The Company’s technology transfer agreement is an innovative evolution of a longstanding collaboration that will ensure a sustainable supply of atazanavir in the future for the many patients who can benefit from the therapy in Brazil,” said Mark Pavao, president, Emerging Markets, Bristol-Myers Squibb. “The agreement also provides an opportunity to increase access to this medicine and supports the Brazilian government’s interests in the further development of its local pharmaceutical manufacturing base.”